Pfizer has announced this Monday that his vaccine against COVID-19 is safe and effective in children from 5 to 11 years old, at a time of strong increase in cases of contagion between minors and with many parents anxious to protect their children. According to the centers for the control and prevention of diseases in the US (CDC), one in five new positives at the national level corresponds to children, with the Delta variant as the main responsible for the increase.
The plan, both from Pfizer and Biontech - which in a community point out that the immune response was "comparable" to that observed in young people aged 16 to 25 who received a higher dose of the vaccine, is to present the drug before administration From US drugs and food (FDA) at the end of the month for approval in the following weeks, perhaps before Halloween, on October 31. There is urgency to stop the income from the children's population in hospitals, at a higher rate in recent weeks than at any other time of the pandemic.
There is a long way to go in that aspect. Only 54.6% of Americans have the complete guideline, a percentage that increases up to 63.9% of over 12 years. The inclusion of children between 5 and 11 should help improve these numbers considerably, while pharmaceuticals work at the drug for children under 5 years. It is not expected that happening until the end of this year or beginnings of 2022.
At a general level, the panorama remains little encouraging. The number of deceased has already exceeded the barrier of the 2,000 per day, 29% more than 14 days ago, and almost a quarter of all those who died by Covid in the world. The positives are around 150,000 daily, although a decrease of 8% has been recorded with respect to two weeks ago.Updated Date: 21 September 2021, 17:08